Phenotypes Associated with This Genotype

Genotype
MGI:3603330

• Allelic Composition: Pten^tm2.1Ppp/Pten^tm2.1Ppp; Trp53^tm1Thl/Trp53^tm1Thl; Tg(Pbsn-cre)4Prb/0
• Genetic Background: involves: 129S1/Sv * C57BL/6 * DBA/2

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:100683 )

• all mutants died by 7 months of age

neoplasm

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53

increased carcinoma incidence ( J:100683 )

• by 11 weeks of age invasive adenocarcinoma develops

renal/urinary system

urinary bladder obstruction ( J:100683 )

• bladder obstruction

kidney failure ( J:100683 )

reproductive system

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53

endocrine/exocrine glands

increased prostate gland tumor incidence ( J:100683 )

♂ • invasive prostatic cancer is seen in all mutants by 10 weeks of age

♂ • average tumor weight is increased 32-fold compared to mutants wild-type for Trp53 and these tumors encompass the entire genitourinary tract and pelvis

♂ • no increase is seen in the number of senescent cells compared to wild-type prostates unlike in mutants wild-type for Trp53